Combination Antibody Therapy Market

Global Market Study on Combination Antibody Therapy: Antibody/Antibody Combination Segment Expected to Dominate the Global Market Through 2024

Combination Antibody Therapy Market Segmented By Chemotherapy/Antibody, Antibody/Antibody, Conjugated Antibodies, Bispecific Antibodies combination for Lung Cancer, Blood Cancer, Breast Cancer, Colorectal Cancer

  • January-2017
  • PMRREP11740
  • 234 Pages
  • Healthcare
  • PPT, PDF, WORD, EXCEL

Antibody/antibody segment is expected to gain significant revenue growth over the forecast period

According to the report, revenue contribution of the chemotherapy/antibody segment to the global combination antibody therapy market was estimated to be close to 40% market share by 2016 end. The chemotherapy/antibody segment is anticipated to exhibit a CAGR of 7.8% in terms of value over the assessed period. This segment is estimated to be valued close to US$ 35 Bn by 2024.

Find Out More about the Report Coverage

Companies

Company Profile

  • Biogen Inc.
  • Roche Holdings AG
  • Seattle Genetics Inc.
  • Amgen incorporated
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Novartis AG
  • Sanofi 
  • Celgene Corp
  • Genmab A/S
  • Others.

Rising incidence of cancer across the globe is anticipated to create a positive impact on the chemotherapy/antibody segment

The first and foremost reason for fueling the growth of the chemotherapy/antibody segment is the rise in the rates of cancer across the globe. Cancer is the second leading cause of death globally after cardiovascular drug for disease. The proportion of deaths around the world due to cancer has increased remarkably in the last few years. According to the World Health Organization (WHO), cancer accounts for more than 8 million deaths each year, with about 70% new cancer cases expected to be reported over the next 20 years.

Each cancer type requires a unique treatment and chemotherapy is one of them. Hence, increasing prevalence of cancer and the need for chemotherapy that is capable of attacking cancer cells throughout the body is driving the growth of the chemotherapy/antibody segment of the global combination antibody therapy market. 

Another factor which is creating robust development in the chemotherapy/antibody segment is that combination antibody therapies are more effective than traditional therapies such as radiation or surgery. Radiation therapy and surgery can remove, damage or kill cancer cells in a particular area; however, combination antibody therapy such as chemotherapy/antibody can work throughout the body.

The effectiveness of combination antibody therapy is creating a positive impact on the chemotherapy/antibody segment. An increasing awareness regarding the treatment options for cancer among people is also fueling the growth of the chemotherapy/antibody segment.

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Chemotherapy/antibody segment projected to gain significant value share in the APAC region during the assessment period

The chemotherapy/antibody segment in the North America region was estimated to be valued at US$ 8,851.1 Mn by 2016 end and is expected to reach US$ 13,951.3 Mn by 2024. The chemotherapy/antibody segment in the North America combination antibody therapy market is expected to increase 1.6X in terms of revenue during the forecast period.

While in Latin America and APAC regions the market share of the chemotherapy/antibody segment is more than 40%. In the APAC region, the chemotherapy/antibody segment was estimated to be valued at more than US$ 2,000 Mn by 2016 end and is expected to reach close to US$ 6000 Mn by 2024. The chemotherapy/antibody segment in the APAC combination antibody therapy market is expected to increase 2.1X in terms of revenue during the forecast period.

combination antibody therapy market

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Key players announce new combination drugs to fight chronic Lymphocytic Leukemia

In 2008, U.S. based company Biogen Inc. announced the successful phase III clinical trials of Rituxan. In combination with chemotherapy, this drug helped improve progression free survival in patients with relapsed chronic Lymphocytic Leukemia. In 2010, the FDA approved Rituxan in combination with chemotherapy drugs such as fladarabinie and cyclophosphamide (FC) for the treatment of the most common type of Adult Leukemia.

Explore Persistence Market Research’s expertise in promulgation of the business !

Market share of key players

The top 10 key players operating in the global combination antibody therapy market collectively contribute approximately 80% revenue share to the global combination antibody therapy market. The remaining players contribute approximately 20% revenue share to the global combination antibody therapy market.

Market segmentation

By combination, the market is segmented into:

 

  • Chemotherapy/Antibody
  • Antibody/Antibody
  • Conjugated Antibodies
  • Bispecific Antibodies

By application, the market is segmented into:

 

  • Lung Cancer
  • Blood Cancer
    • Lymphoma
    • Leukemia
    •  Myeloma
  • Breast Cancer
  • Colorectal Cancer
  • Others

By end user, the market is segmented into:

 

  • Hospitals
  • Cancer research institutes
  • Clinics
  • ASCs

By region, the market is segmented into:

 

  • North America
  • Latin America
  • Europe
  • APAC
  • MEA

Media Release

Recommendations

Compression Therapy Devices Market 092017

Global compression therapy estimated to be worth of revenue US$ 2,929.8 Mn by 2017 end and could expand at a CAGR of 5.4% over the forecast period of 2017–2025.

Alexandrite Laser Treatment Market

Alexandrite Laser Treatment Market study report offers comprehensive data and information about the important market dynamics and associated growth parameters.

Polycystic Ovarian Syndrome Drugs Market

Global polycystic ovary syndrome drugs market revenue is estimated to reach US$ 1,154.8 Mn by 2024, expanding at a CAGR of 4.6% during the forecast period 2016–2024.

Hepatitis C Treatment Market

Global hepatitis C treatment market is projected to be valued at US$ 23.9 Bn by the end of 2015 and is further expected to reach US$ 71.13 Bn by 2024 end, registering a CAGR of 13.1%.

Our Clients

Our Clients